Adenosine Deaminase-Severe Combined Immunodeficiency Market Report 2026

Adenosine Deaminase-Severe Combined Immunodeficiency Market Overview

• Adenosine Deaminase-Severe Combined Immunodeficiency market size has reached to $5.94 billion in 2025 • Expected to grow to $8.11 billion in 2030 at a compound annual growth rate (CAGR) of 6.4% • Growth Driver: Impact Of Rising Genetic Disorder Prevalence On The Market • Market Trend: Innovations In Gene Therapy Enhance Treatment Options For Adenosine Deaminase-Severe Combined Immunodeficiency (ADA-SCID) • North America was the largest region in 2025.

What Is Covered Under Adenosine Deaminase-Severe Combined Immunodeficiency Market?

Adenosine deaminase-severe combined immunodeficiency (ADA-SCID) is a rare genetic disorder caused by a deficiency of the enzyme adenosine deaminase, leading to the toxic accumulation of metabolites that impair immune cell development. The purpose of understanding ADA-SCID is to diagnose and manage the condition early, preventing life-threatening infections and complications. The main treatment type of adenosine deaminase-severe combined immunodeficiency includes enzyme replacement therapy, gene therapy, stem cell transplantation, and supportive care treatments. Enzyme replacement therapy (ERT) is a medical treatment that involves administering synthetic or recombinant enzymes to replace a deficient or absent enzyme in individuals with certain genetic disorders. These therapies are administered through various routes, including intravenous, subcutaneous, and oral. They are designed for both pediatric and adult patients and are distributed through hospital, retail, and online pharmacies. Key end-users include hospitals, specialty clinics, research institutes, and others.

What Is The Adenosine Deaminase-Severe Combined Immunodeficiency Market Growth Forecast?

The adenosine deaminase-severe combined immunodeficiency market size is expected to see strong growth in the next few years. It will grow to $8.11 billion in 2030 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to advancements in autologous stem cell therapies, increasing enzyme replacement therapy accessibility, growth in specialized hospitals and clinics, rising pediatric diagnosis rates, increasing healthcare funding for rare genetic disorders. Major trends in the forecast period include increasing adoption of enzyme replacement therapies, rising development and access to gene therapy solutions, growth in stem cell transplantation procedures, expansion of pediatric treatment programs for ada-scid, enhanced focus on supportive care and patient monitoring.

Global Adenosine Deaminase-Severe Combined Immunodeficiency Market Segmentation

1) By Treatment Type: Enzyme Replacement Therapy (ERT), Gene Therapy, Stem Cell Transplantation, Supportive Care Treatments 2) By Route of Administration: Intravenous, Subcutaneous 3) By End-User: Hospitals, Specialty Clinics Subsegments: 1) By Enzyme Replacement Therapy (ERT): Pegylated Adenosine Deaminase, Non-Pegylated Adenosine Deaminase 2) By Gene Therapy: Autologous Stem Cell-Based Gene Therapy, Viral Vector-Mediated Gene Therapy 3) By Stem Cell Transplantation: HLA-Matched Bone Marrow Transplant, Umbilical Cord Blood Transplant 4) By Supportive Care Treatments: Antimicrobial Therapy, Immune System Support

What Is The Driver Of The Adenosine Deaminase-Severe Combined Immunodeficiency Market?

The rising prevalence of genetic disorders is expected to propel the growth of the adenosine deaminase-severe combined immunodeficiency market going forward. Genetic disorders refer to medical conditions caused by abnormalities or mutations in an individual's DNA, either inherited or occurring spontaneously. The rising prevalence of genetic disorders is driven by factors such as improved diagnostic technologies, increased awareness, higher parental age, environmental influences, and population growth. The rising prevalence of genetic disorders, particularly in conditions such as adenosine deaminase-severe combined immunodeficiency (ADA-SCID), drives increased demand for advanced diagnostic methods and targeted treatments. For instance, in October 2024, according to the Cystic Fibrosis Trust, a UK-based national charity, 11,148 people were living with cystic fibrosis (CF) in the UK in 2022, increasing to 11,318 in 2023. Therefore, the rising prevalence of genetic disorders is driving the growth of the adenosine deaminase-severe combined immunodeficiency industry.

Key Players In The Global Adenosine Deaminase-Severe Combined Immunodeficiency Market

Major companies operating in the adenosine deaminase-severe combined immunodeficiency market are GlaxoSmithKline plc, Chiesi Farmaceutici S.p.A., Orchard Therapeutics PLC, Rocket Pharmaceuticals, Novartis AG, Bluebird Bio, Spark Therapeutics, Leadiant Biosciences, Sigma-Tau Pharmaceuticals, Astellas Pharma, Takeda Pharmaceutical Company, Pfizer Inc, Sanofi, Bristol-Myers Squibb, Roche Holding AG, Johnson & Johnson, AbbVie Inc, Gilead Sciences, CSL Limited, Bayer AG

Global Adenosine Deaminase-Severe Combined Immunodeficiency Market Trends and Insights

Major organizations operating in the adenosine deaminase-severe combined immunodeficiency treatment market are focusing on developing advanced solutions, such as in-house gene therapy production, to improve patient access, reduce treatment costs, and ensure supply continuity. In-house gene therapy production refers to the strategy of producing autologous hematopoietic stem cells genetically modified with a healthy ADA gene within the organization’s own facility, reducing dependence on commercial manufacturers. For instance, in February 2025, the Fondazione Telethon, an Italy-based nonprofit biomedical research organization, submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for etuvetidigene autotemcel, a gene therapy originally developed for ADA-SCID and now also targeting Wiskott-Aldrich Syndrome. The therapy consists of a single administration of autologous CD34+ stem and progenitor cells transduced with a lentiviral vector encoding the functional gene, showing promising safety and efficacy outcomes in treated patients.

What Are Latest Mergers And Acquisitions In The Adenosine Deaminase-Severe Combined Immunodeficiency Market?

In January 2024, Kyowa Kirin Co., Ltd., a Japan-based pharmaceutical company, acquired Orchard Therapeutics plc. for an undisclosed amount. The acquisition aimed to strengthen Kyowa Kirin's focus on creating innovative treatments for rare and complex diseases by leveraging Orchard Therapeutics' gene therapy platform. Orchard Therapeutics plc is a UK-based gene therapy company that specializes in developing gene therapies for rare genetic diseases.

Regional Outlook

North America was the largest region in the adenosine deaminase-severe combined immunodeficiency market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Adenosine Deaminase-Severe Combined Immunodeficiency Market?

The adenosine deaminase-severe combined immunodeficiency market consists of revenues earned by entities by providing services such as diagnosis and genetic testing, therapy services, and consultation & genetic counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The adenosine deaminase-severe combined immunodeficiency market also includes sales of diagnostic tools, supportive therapies, and genetic testing kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Adenosine Deaminase-Severe Combined Immunodeficiency Market Report 2026?

The adenosine deaminase-severe combined immunodeficiency market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the adenosine deaminase-severe combined immunodeficiency industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.